AMGEN OUTLINES GROWTH STRATEGY THROUGH 2030 AT VIRTUAL BUSINESS REVIEW

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today outlined its growth strategy through 2030, a period during which the Company expects to deliver attractive financial...

Related Keywords

Rhode Island ,United States ,United Kingdom ,China ,Puerto Rico ,Japan ,North Carolina ,Ohio ,Canada ,Susan Sweeney ,Ray Deshaies ,David Reese ,Michael Strapazon ,Megan Fox ,Alan Russell ,Roberta Bradway ,Murdo Gordon ,Peter Griffith ,Amgen ,Astrazeneca ,Therapeutics Inc ,Arrakis Therapeutics Inc ,Development Reconceiving Drug Discovery ,Teneobio Inc ,Food Drug Administration ,Kyowa Kirin Co Ltd ,Regeneron Pharmaceuticals Inc ,Amgen Foundation Inc ,Plexium Inc ,Beigene Ltd ,Alexion Pharmaceuticals Inc ,Exchange Commission ,Biomedicines Inc ,National Reimbursement Drug List ,Amgen Inc ,Amgen Research ,Amgen Safety Net Foundation ,Amgen Foundation ,North Star ,Delivering Long Term ,Compound Annual Growth Rate ,Strong Revenue Growth Over ,Global Commercial Operations ,Global Marketing ,Worldwide Otezla ,Drug Administration ,General Medicine ,Nature Medicine ,Generate Biomedicines ,Amgen Safety Net ,Janssen Pharmaceutica ,Regeneron Pharmaceuticals ,Alexion Pharmaceuticals ,Investor Relations Events ,Dow Jones Industrial Average ,Best Workplaces ,Great Place ,Arrakis Therapeutics ,Five Prime Therapeutics ,Thousand Oaks ,Year Ending December ,Rate Guidance ,Adjusted Financial ,